加速间歇性甲基突破刺激对调节阿尔茨海默氏病的大脑的影响
Hua Lin1, Junhua Liang1, Qianqian Wang1
1Department of Neurology, Xuanwu Hospital, Capital Medical University, 45th, Changchun Street, Beijing 100053, China.
Cerebral cortex (New York, N.Y. : 1991)
|March 22, 2024
概括
加速间歇性甲基突发刺激 (aiTBS) 在早期阿尔茨海默病 (AD) 患者中改善了认知功能和增强了大脑活动. 这种新的治疗方法证明了安全性和耐受性,为AD提供了有前途的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗器械 医疗器械
背景情况:
- 阿尔茨海默病 (AD) 构成了重大挑战,有效治疗方法有限.
- 非侵入性脑刺激技术正在探索在AD治疗中的治疗应用.
- 加快间歇性甲型突发刺激 (aiTBS) 是一种用于大脑调节的新高剂量方案.
研究的目的:
- 在早期阿尔茨海默病 (AD) 患者中研究加速间歇性甲基突发刺激 (aiTBS) 的疗效和安全性.
- 评估aiTBS对AD认知功能和皮质刺激性的影响.
- 为了阐明神经生理机制背后的aiTBS在AD的影响.
主要方法:
- 一项随机对照试验,涉及45名早期阿尔茨海默病患者,接受真实或假的aiTBS.
- 在治疗前和治疗后进行了神经心理评估,包括听觉语言学习测试.
- 单脉冲的跨脑磁性刺激 (TMS) 与脑电图 (EEG) (TMS-EEG) 结合使用来测量皮质刺激性和振荡活动.
主要成果:
- 与基线相比,真正的aiTBS显著改善了听力口语学习测试成绩.
- 在对aiTBS的反应中,TMS-EEG显示皮质刺激性增加和β振荡活性增强.
- 治疗aiTBS导致了目标大脑区域局部自然频率的增强.
结论:
- 高剂量的aiTBS针对左侧脊侧前额皮质 (DLPFC) 是一种快速起作用,安全和耐受的治疗早期的AD.
- aiTBS通过调节特定的神经振荡来有效地改善AD的认知障碍.
- 这些发现支持aiTBS作为阿尔茨海默病的有希望的非侵入性治疗策略.
相关概念视频
Brain Imaging
228
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
228
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184


